Free Trial
NASDAQ:AKTX

Akari Therapeutics (AKTX) Stock Price, News & Analysis

Akari Therapeutics logo
$1.27 +0.02 (+1.61%)
Closing price 05/23/2025 03:56 PM Eastern
Extended Trading
$1.30 +0.02 (+1.57%)
As of 05/23/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Akari Therapeutics Stock (NASDAQ:AKTX)

Key Stats

Today's Range
$1.21
$1.37
50-Day Range
$1.07
$1.53
52-Week Range
$0.85
$4.40
Volume
13,550 shs
Average Volume
31,858 shs
Market Capitalization
$41.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

Receive AKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AKTX Stock News Headlines

Akari Therapeutics (NASDAQ:AKTX) Now Covered by StockNews.com
Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
See More Headlines

AKTX Stock Analysis - Frequently Asked Questions

Akari Therapeutics' stock was trading at $1.22 at the beginning of the year. Since then, AKTX stock has increased by 4.5% and is now trading at $1.2750.
View the best growth stocks for 2025 here
.

Akari Therapeutics, Plc (NASDAQ:AKTX) posted its quarterly earnings data on Tuesday, March, 31st. The biopharmaceutical company reported ($7.80) EPS for the quarter, missing the consensus estimate of ($2.80) by $5.00.

Shares of Akari Therapeutics reverse split before market open on Thursday, August 17th 2023. The 1-20 reverse split was announced on Thursday, August 17th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Shares of AKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Akari Therapeutics investors own include NVIDIA (NVDA), CymaBay Therapeutics (CBAY), Broadcom (AVGO), Novo Nordisk A/S (NVO), Adobe (ADBE), Meta Platforms (META) and GE Aerospace (GE).

Company Calendar

Last Earnings
3/31/2020
Today
5/24/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AKTX
Employees
9
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
($0.03) per share
Price / Book
-42.50

Miscellaneous

Free Float
16,248,000
Market Cap
$41.02 million
Optionable
Not Optionable
Beta
0.29
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:AKTX) was last updated on 5/24/2025 by MarketBeat.com Staff
From Our Partners